ENST00000361681.2:c.187A>G

Variant summary

Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PS4PP1_ModeratePP3PM2_SupportingPS3_Moderate

This summary comes from the ClinGen Evidence Repository: The m.14487T>C (p.M63V) variant in MT-ND6 has been reported in at least 37 unrelated individuals with primary mitochondrial disease (PS4; PMIDs: 30741831, 33706792, 34223155, 32162843, 30461153, 30128709, 30095618, 28122886, 28429146, 27338358, 26530508, 23813926, 23463613, 24126373, 23847141, 23010433, 21364701, 21196529, 19062322, 18977334, 17535832, 16044424, 15625630, 15576045, 14595656, 14520668, 14684687, 20019223). Features seen in affected individuals include Leigh syndrome spectrum and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as ataxia, dystonia, epilepsy, optic neuropathy, and ptosis. Heteroplasmy levels were variable in affected individuals as was age of onset (infancy to adulthood). This variant segregated with disease in multiple affected members in multiple families and several healthy family members had lower to undetectable levels of the variant (PP1_moderate; PMIDs: 14684687,17535832, 20019223, 24126373, 26530508, 28122886). This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.9 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3). Cybrid studies have shown independent functional consequences (PS3_moderate) including almost undetectable rotenone-dependent oxygen consumption (PMID 14520668), an overproduction of reactive oxygen species (ROS, PMID 16337195), and decreased complex I activity corresponding with heteroplasmy levels as well as decreased levels of fully assembled complex I (PMID 14595656). In summary, this variant meets criteria to be classified as pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on August 8, 2022. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID:32906214): PS4, PP1_moderate, PM2_supporting, PP3, PS3_moderate. LINK:https://erepo.genome.network/evrepo/ui/classification/CA120627/MONDO:0044970/014

Frequency

Mitomap GenBank:
Absent

Consequence

MT-ND6
ENST00000361681.2 missense

Scores

Apogee2
Pathogenic
0.95

Clinical Significance

Pathogenic reviewed by expert panel P:6O:1
Dystonia-/-Leigh-Disease-/-ataxia-/-ptosis-/-epilepsy

Conservation

PhyloP100: 3.75

Publications

22 publications found
Variant links:
Genes affected
MT-ND6 (HGNC:7462): (mitochondrially encoded NADH dehydrogenase 6) Enables NADH dehydrogenase (ubiquinone) activity. Involved in mitochondrial electron transport, NADH to ubiquinone and mitochondrial respiratory chain complex I assembly. Predicted to be located in mitochondrial inner membrane. Implicated in Leber hereditary optic neuropathy; Leigh disease; and spinal muscular atrophy with lower extremity predominante 2B. [provided by Alliance of Genome Resources, Apr 2022]
TRNE (HGNC:7479): (mitochondrially encoded tRNA glutamic acid)
TRNE Gene-Disease associations (from GenCC):
  • mitochondrial disease
    Inheritance: Mitochondrial Classification: DEFINITIVE Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 10 ACMG points.

PS3
For more information check the summary or visit ClinGen Evidence Repository.
PS4
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.
PP1
For more information check the summary or visit ClinGen Evidence Repository.
PP3
For more information check the summary or visit ClinGen Evidence Repository.

Variant Effect in Transcripts

ACMG analysis was done for transcript: ENST00000361681.2. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt

There are no transcript annotations for this variant.

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
MT-ND6
ENST00000361681.2
TSL:6
c.187A>Gp.Met63Val
missense
Exon 1 of 1ENSP00000354665.2P03923
MT-TE
ENST00000387459.1
TSL:6
n.*187A>G
downstream_gene
N/A

Frequencies

Mitomap GenBank
The variant is not present, suggesting it is rare.
Alfa
AF:
0.00
Hom.:
0

Mitomap

Disease(s): Dystonia-/-Leigh-Disease-/-ataxia-/-ptosis-/-epilepsy
Status: Cfrm-[P]
Publication(s): 14595656

ClinVar

ClinVar submissions
Significance:Pathogenic
Revision:reviewed by expert panel
View on ClinVar
Pathogenic
VUS
Benign
Condition
1
-
-
Leber optic atrophy (1)
1
-
-
Leigh syndrome (2)
1
-
-
Leigh syndrome due to mitochondrial complex I deficiency (1)
1
-
-
MELAS syndrome (1)
1
-
-
Mitochondrial disease (1)
1
-
-
Striatal necrosis, bilateral, with dystonia (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
Apogee2
Pathogenic
0.95
Hmtvar
Pathogenic
0.87
AlphaMissense
Pathogenic
0.87
BayesDel_addAF
Benign
-0.50
T
DEOGEN2
Pathogenic
0.85
D
LIST_S2
Benign
0.86
D
MutationAssessor
Pathogenic
3.9
H
PhyloP100
3.8
PROVEAN
Uncertain
-4.0
D
Sift
Pathogenic
0.0
D
Sift4G
Pathogenic
0.0
D
GERP RS
4.0
Varity_R
0.81
Mutation Taster
=90/10
polymorphism

Publications

Other links and lift over

dbSNP: rs199476109; hg19: chrM-14488; API
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.